EFSA’s NDA Panel assessed L-alpha-GPC manufactured from soy phospholipids and concluded that it raises no safety concern under the proposed conditions of use. The dossier covers liquid and powder forms with defined specifications and manufacturing.

The evaluated use is in supplements at up to 203.7 mg per day, equivalent to 82.5 mg choline, for people over three years of age, including pregnant and lactating women. Its soy origin keeps allergen requirements relevant.

For formulation and procurement, the opinion provides a useful technical perimeter covering identity, impurities, dose and target population. For scientific marketing, the boundary is equally important: a safety conclusion does not demonstrate cognitive efficacy.

The opinion is one stage of the Novel Food process and should not be communicated as final authorisation or approval of health claims. Authorisation status, conditions of use and relevant evidence require separate verification.

Why it matters

The conclusion supports formulation work while requiring a clear separation between Novel Food safety, cognitive efficacy and permissible claims.

Evidence limit

This is a scientific safety opinion, not final European Commission authorisation and not validation of benefits for memory, focus or performance.

Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.

Read the original source · EFSA Journal ↗